PT Bundamedik Tbk

Analyst Meeting – 1Q23 Results

May 2023

Disclaimer:

Presentation are intended for educational purposes only and do not replace independent professional judgement. Statements of fact and opinions are those of the participants individually and, unless expressly stated to the contrary. Specific data in this presentation was obtained from various external data sources, and the Company has not verified such data with independent sources. Accordingly, the Company makes no representations as to the occurrence, accuracy or completeness of that data, and such data involves risks and uncertainties and is subject to change based on various factors.



Leading Provider in Specialized Healthcare Services since 1973









rsia bunda Jakarta
















imtb




CONTRACTOR OF THE OWNER OWNER OWNER OWNER OWNE

Bundamedik Tbk (BMHS)

1Q23 Key Highlights





Our commitment to serve better From embryo throughout life

Diagnos

DIVERSION OF









1Q23 Results





\$















Financial & Operational Performance Flat QoQ growth; Initiatives in place to improve performance



		HIG	HLIGHTS O	F CONSOLIDATE	D RESULT	
	4Q22	1Q23	QoQ (%)	YTD Mar 22	YTD Mar 23	YoY (%)
OPERATIONALS						
# Outpatient	134.6	133.6	-1%	107.8	133.6	24%
# Inpatient Days	24.8	23.4	-6%	28.4	23.4	-18%
# Inpatient Admission	9.5	9.8	3%	7.2	9.8	37%
# Surgery	2.9	3.3	16%	2.6	3.3	26%
# Beds	631	631	0%	506	631	25%
BOR (%)	43%	41%		62%	41%	
BOR Existing (%)	50%	47%		73%	47%	
BOR New (%)	58%	28%		14%	28%	
# IVF Cycles	1.39	1.38	-0.6%	1.39	1.38	-0.4%
# Lab Test (Diagnos)	239.2	171.7	-28%	265.0	171.7	-35%
# Lab Test (Diagnos - non Covid)	212.1	158.4	-25%	171.9	158.4	-8%
PROFIT LOSS						
Gross Revenue	430	385	-10%	419	385	-8%
Net Revenue	378	332	-12%	373	332	-119
Gross Profit	189	182	-3%	193	182	-5%
GPM (%) to net	50%	55%	10%	52%	55%	79
EBITDA	83	60	-27%	90	60	-32%
EBITDA Margin (%) to net	22%	18%		24%	18%	
Net Profit	21	15	-31%	46	15	-68%
NPM (%)	5%	4%		11%	4%	
NP attributable to:						
Owners of the parent	10	9	-10%	31	9	-719
Non-controlling interests	11	4	-64%	15	4	-73%

Key Notes

0	 Core Business in 1Q23 Hospitals metrics: mostly grew in #Outpatients, #IP Admission and #surgeries, but #IP Days declined by -18% YoY Morula - Flat # of cycles YoY and QoQ Diagnos - Significant decline in # of test post Covid-19 pandemic
2	 Gross Revenue YoY decreased by 8% YoY, due to: Diagnos revenue declined 54% YoY as Covid related tests significantly reduced Morula revenue declined 17% YoY due to closure of non-core low margin IVF related pharma trading/distribution business Hospital revenue increased by 3% YoY Improvement in Consolidated Gross Profit Margin Resulted from supply chain optimization
3	 Compression in Consolidated EBITDA margin Diagnos EBITDA decline by Rp 14bn on the back of lower revenue and higher operational costs of non-performing outlets Diagnos started to right-size the business in Feb-23 by closing eight non-performing outlets, resulting in monthly Opex reduction (see slide 12) Morula Higher salaries and operational expenses, driven by new Morula Hospitals in Surabaya and Bali by Rp 3bn.

Evaluating cost-structure for further efficiency program

















imtb





Hospitals Volume











All units in '000


















Financial Performance Consolidated





Balance Sheet Remains healthy

Diagnos

DIVERSION OF

PBUNDA

a morulaivf

BGP




14

imtb

RSJP PARAMARTA BUNDA

PINTAR

P




PBIC CLINIC

<u> 6 BDI</u>





OF IVF CYCLES ('000)





🍈 🍈 🎆 👘 🎆

Diagnos

DISIDE LABOR OFF










BUNDA PINTAR

2023 Initiatives: Morula





Morula Dragon Baby Package in anticipation for Dragon year in 2024





















Diagnos Rightsizing Capacity post Covid





- Close 8 underperforming outlets, bringing 31 outlets as of Mar-23
- Promising Genomic business, contributing 15% of revenue





Strengthening Our Core




















Employing Advanced Technology Higher Success Rate





Fertility Acupuncture



Note: 1) Internal data based on 2019 – 30Sep22
















Fertility Wellness

Fertility Food

Morula Services





Strengthening Our COEs







Klinik Tumbuh Kembang Anak











Bunda Health Center





Bunda General Hospital Bunda Women & Children Hospital Jakarta





















Ensuring Standardised Quality Process











QKARS





REPRODUCTIVE TECHNOLOGY ACCREDITATION COMMITTEE

0






























2023 Outlook





s.















2023 Key Focus Area























2023 Strategy



New Hospitals	Cost efficiency	Morula	Diagnos
 Financial optimization implemented through revenue and cost improvement levers (e.g., ARPP, better procurement, etc.), expected done in 3-4Q23 Operation excellence conducted through patient journey, clinical outcomes, and lean operation all year round Data and IT architecture developed to support business operation throughout the year. 	 Ideal BPJS case mix that would drive better revenue and margin Optimum patient source mix that hospitals should aim for Procurement transformation savings through centralized procurement, negotiation and formulary change, All of these cost efficiency will impact ~1% improvement on EBITDA Margin and expected done in 3Q23. 	 Strengthen KFI performance to enhance morula brand positioning through obgyn referral throughout the year Better margin through centralized procurement with BGP done in 1Q23 Improve marketing, sales & key account to build brand awareness through B2B market, referral program, and national scale mass production in 2Q23 	 Footprint expansion reviewed across all outlets and expected until 2Q23 Strengthen commercial strategy to improve customer retention and loyalty until 3Q23 Strengthen genomics revenue through strategic partnership and marketing activity at the beginning of the year

Overall corporate initiatives

- 1. Digital business scaled to expand reach, acquire more users, and build stickiness
 - **Business integration** with **Bunda core business** to improve value proposition
 - **Digital integration and loyalty program** developed for Bunda and partner network
- 2. Capex excellence implemented to improve capital efficiency
- 3. Group level synergy for KPI and performance monitoring systems that need to be in place




















Our New Booking Platform









0

-17 12

4

.

5

5

80

2

2.

2.0

30

1

OncBundb

Pluh Lakest

INSIA BURGA Skiense

050 City Hasper

BI Drawn

berti Kanta A.

E Ril Bunda Manganda


BRIS Barra Cloure


E C vice

DCPF

IND BARANCE KAN

Links









Solver Dr. Natal A shash ISBunda ja se

🔵 GneBunda



Antenatal Care Book *

* ready by 2nd week of May 2023





New Booking Platform













2023 Network Planning





RSIA Bunda Jakarta Renovation

Building renewal & rejuvenation for our signature hospital. Expect to finish early 2024.



RSIA Bunda Dewata

Fully operate as W&C Hospital in Mar23. Type C hospital with 25 bed capacity.



Bunda Morula Nusa Dua

Morula add presence in Bali area to cater domestic and tourist patient. Currently operate as outpatient clinic.



















THANK YOU

Disclaimer:

Presentation are intended for educational purposes only and do not replace independent professional judgement. Statements of fact and opinions are those of the participants individually and, unless expressly stated to the contrary. Specific data in this presentation was obtained from various external data sources, and the Company has not verified such data with independent sources. Accordingly, the Company makes no representations as to the occurrence, accuracy or completeness of that data, and such data involves risks and uncertainties and is subject to change based on various factors.



PT Bundamedik Tbk Jl. Teuku Cik Ditiro No. 28 Menteng, Jakarta Pusat 1-500-799|info@bmhs.co.id

